Sansure Biotech Inc. (688289.SS)
CNY 19.81
(-0.4%)
CNY 19.81
(-0.4%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 996.81 Million CNY | -39.99% |
| 2022 | 1.66 Billion CNY | 134.26% |
| 2021 | 709.02 Million CNY | 0.01% |
| 2020 | 708.94 Million CNY | 734.17% |
| 2019 | 84.98 Million CNY | -45.43% |
| 2018 | 155.75 Million CNY | -16.54% |
| 2017 | 186.62 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.21 Billion CNY | 7.21% |
| 2024 Q1 | 1.21 Billion CNY | 22.03% |
| 2024 Q2 | 1.13 Billion CNY | -6.6% |
| 2023 Q4 | 996.81 Million CNY | 13.44% |
| 2023 FY | 996.81 Million CNY | -39.99% |
| 2023 Q3 | 878.68 Million CNY | -11.67% |
| 2023 Q1 | 1.15 Billion CNY | -30.59% |
| 2023 Q2 | 994.79 Million CNY | -13.71% |
| 2022 Q3 | 864.77 Million CNY | -3.93% |
| 2022 Q2 | 900.18 Million CNY | 9.83% |
| 2022 Q1 | 819.62 Million CNY | 15.6% |
| 2022 FY | 1.66 Billion CNY | 134.26% |
| 2022 Q4 | 1.66 Billion CNY | 92.07% |
| 2021 Q4 | 709.02 Million CNY | 0.59% |
| 2021 Q2 | 637.72 Million CNY | -26.15% |
| 2021 Q1 | 863.58 Million CNY | 21.81% |
| 2021 Q3 | 704.88 Million CNY | 10.53% |
| 2021 FY | 709.02 Million CNY | 0.01% |
| 2020 Q3 | 718.44 Million CNY | 1.12% |
| 2020 Q4 | 708.94 Million CNY | -1.32% |
| 2020 Q2 | 710.48 Million CNY | 154.94% |
| 2020 Q1 | 278.68 Million CNY | 227.91% |
| 2020 FY | 708.94 Million CNY | 734.17% |
| 2019 Q4 | 84.98 Million CNY | 0.0% |
| 2019 FY | 84.98 Million CNY | -45.43% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 FY | 155.75 Million CNY | -16.54% |
| 2017 FY | 186.62 Million CNY | 0.0% |